Coagulation factor VIIa recombinant human

Coagulation factor VIIa recombinant human is a genetically engineered form of activated human coagulation Factor VII (rFVIIa), produced in hamster kidney cells. It is a vitamin K-dependent glycoprotein that plays a critical role in the extrinsic pathway of the coagulation cascade. The drug is used to treat and prevent bleeding episodes in patients with hemophilia A or B who have developed inhibitors to Factor VIII or IX, as well as for patients with acquired hemophilia, congenital Factor VII deficiency, and Glanzmann's thrombasthenia unresponsive to platelet transfusions[1][2][5]. Mechanistically, rFVIIa promotes hemostasis by binding tissue factor at sites of vascular injury, activating Factor X to Xa and Factor IX to IXa, which leads to thrombin generation and fibrin clot formation[5][6][8]. At pharmacologic doses, it can also directly activate platelets and enhance local clotting even when other factors are deficient[6].

Brand names

NovoSevenNovoSeven RTSevenfactNiastase RT

Other names

eptacog alfarecombinant FVIIa